Research is focused on reducing over-activation of the intracellular inflammatory cascade. By therapeutically engaging with this process, it is possible to reduce the release of inflammatory cytokines and other inflammatory molecules and so ease inflammation
Carocell Bio’s therapeutic molecules are short proteins (“peptides”) that are highly selective for mitogen-activated protein kinase (MAPK, p38α), an important component in this intracellular inflammation cascade. Combining these peptides with an established nano-polymer delivery system enhances delivery into the cells. The treatments are designed to be delivered topically rather than systemically and the peptides are simply broken down into amino acids so they are likely to provide a much safer option compared with existing therapies
UK: +44 (0) 161 532 8751
US: +1 307 409 5778
Carocell Bio, Inc.
500 Delaware Avenue
Carocell Bio Ltd.
Cheadle Royal Business Park
Copyright Carocell Bio Ltd. ©2020